Invivyd (IVVD) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
6 Apr, 2026Voting matters and shareholder proposals
Six nominees are up for election to the board of directors for a one-year term expiring at the 2027 annual meeting.
Ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, is proposed.
Additional business may be addressed if properly brought before the meeting or any adjournment.
Board of directors and corporate governance
The board consists of six nominees: Tamsin Berry, Paul B. Bolno, M.D., Marc Elia, Terrance McGuire, Kevin F. McLaughlin, and Ajay Royan.
Directors are elected for one-year terms, with annual elections.
Audit committee and external auditor matters
PricewaterhouseCoopers LLP is recommended for ratification as the independent auditor for the 2026 fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Invivyd
- VYD2311 and VMS063 advance in pivotal COVID-19 and measles studies, targeting urgent unmet needs.IVVD
Study update9 Apr 2026 - Six independent directors up for election and auditor ratification headline the annual meeting.IVVD
Proxy filing6 Apr 2026 - Q4 PEMGARDA revenue up 25% YoY to $17.2M; DECLARATION trial fully enrolled for mid-2026 data.IVVD
Q4 20255 Mar 2026 - Strong early uptake of PEMGARDA supports $150–$200M revenue guidance and robust cash outlook.IVVD
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - PEMGARDA launch drove $2.3M Q2 revenue, but cash runway is under one year.IVVD
Q2 20241 Feb 2026 - Pemgarda sees strong launch in immunocompromised COVID-19 prevention; next-gen antibody in trials.IVVD
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Rapid Pemgarda launch targets unmet needs in immunocompromised COVID-19 patients.IVVD
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - PEMGARDA shows 84%-85% efficacy in COVID-19 prevention, targeting millions at high risk.IVVD
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - Pemgarda leads COVID-19 prevention for immunocompromised, with strong efficacy and market growth.IVVD
Guggenheim Securities Inaugural Healthcare Innovation Conference14 Jan 2026